Precision BioSciences (DTIL) Competitors $5.03 +0.02 (+0.30%) As of 11:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DTIL vs. TRDA, SGMT, ENGN, GNFT, CRGX, ACIU, HRTX, OGI, AARD, and IPHAShould you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Entrada Therapeutics (TRDA), Sagimet Biosciences (SGMT), enGene (ENGN), GENFIT (GNFT), CARGO Therapeutics (CRGX), AC Immune (ACIU), Heron Therapeutics (HRTX), Organigram Global (OGI), Aardvark Therapeutics (AARD), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry. Precision BioSciences vs. Its Competitors Entrada Therapeutics Sagimet Biosciences enGene GENFIT CARGO Therapeutics AC Immune Heron Therapeutics Organigram Global Aardvark Therapeutics Innate Pharma Precision BioSciences (NASDAQ:DTIL) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Do insiders & institutionals hold more shares of DTIL or TRDA? 38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 4.5% of Precision BioSciences shares are held by company insiders. Comparatively, 8.1% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher valuation & earnings, DTIL or TRDA? Entrada Therapeutics has higher revenue and earnings than Precision BioSciences. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecision BioSciences$68.70M0.86$7.17M-$8.81-0.57Entrada Therapeutics$210.78M1.02$65.63M-$1.78-3.19 Does the media refer more to DTIL or TRDA? In the previous week, Entrada Therapeutics had 2 more articles in the media than Precision BioSciences. MarketBeat recorded 3 mentions for Entrada Therapeutics and 1 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.87 beat Entrada Therapeutics' score of 1.73 indicating that Precision BioSciences is being referred to more favorably in the media. Company Overall Sentiment Precision BioSciences Very Positive Entrada Therapeutics Very Positive Which has more risk & volatility, DTIL or TRDA? Precision BioSciences has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500. Is DTIL or TRDA more profitable? Entrada Therapeutics has a net margin of -92.30% compared to Precision BioSciences' net margin of -6,205.79%. Entrada Therapeutics' return on equity of -17.81% beat Precision BioSciences' return on equity.Company Net Margins Return on Equity Return on Assets Precision BioSciences-6,205.79% -176.47% -69.05% Entrada Therapeutics -92.30%-17.81%-14.55% Do analysts recommend DTIL or TRDA? Precision BioSciences presently has a consensus price target of $47.00, suggesting a potential upside of 835.32%. Entrada Therapeutics has a consensus price target of $25.67, suggesting a potential upside of 352.44%. Given Precision BioSciences' higher possible upside, equities analysts plainly believe Precision BioSciences is more favorable than Entrada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Entrada Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryEntrada Therapeutics beats Precision BioSciences on 12 of the 16 factors compared between the two stocks. Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DTIL vs. The Competition Export to ExcelMetricPrecision BioSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.25M$3.08B$5.75B$9.82BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-0.5721.1830.8726.51Price / Sales0.86394.02464.97121.10Price / CashN/A44.4437.7659.36Price / Book1.748.1410.186.69Net Income$7.17M-$54.08M$3.27B$265.51M7 Day Performance6.01%2.97%2.95%3.35%1 Month Performance-1.47%4.09%4.16%1.00%1 Year Performance-48.30%19.11%45.06%23.48% Precision BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DTILPrecision BioSciences4.0129 of 5 stars$5.03+0.3%$47.00+835.3%-48.4%$59.25M$68.70M-0.57200TRDAEntrada Therapeutics3.149 of 5 stars$5.63-8.3%$25.67+355.9%-66.0%$233.55M$210.78M-3.16110SGMTSagimet Biosciences2.9814 of 5 stars$7.08-0.4%$25.67+262.5%+155.9%$231.23M$2M-3.878Gap UpENGNenGene3.119 of 5 stars$4.30-0.5%$23.29+441.5%-33.5%$220.77MN/A-2.6131Gap DownGNFTGENFIT1.9566 of 5 stars$4.19-4.5%$9.00+115.1%+3.4%$219.08M$76.77M0.00120News CoveragePositive NewsGap UpCRGXCARGO Therapeutics2.0443 of 5 stars$4.47flat$15.40+244.5%N/A$216.17MN/A-0.96116ACIUAC Immune2.0476 of 5 stars$2.07-3.7%$12.00+479.7%-32.4%$215.88M$31.02M-3.57140HRTXHeron Therapeutics4.0698 of 5 stars$1.38-1.4%$4.50+226.1%-29.5%$214.61M$144.29M-69.00300OGIOrganigram Global0.3985 of 5 stars$1.63+1.9%N/A-8.7%$214.48M$117.47M32.61860AARDAardvark TherapeuticsN/A$9.04-7.5%$32.80+262.8%N/A$211.98MN/A0.0018High Trading VolumeIPHAInnate Pharma2.4332 of 5 stars$2.20-2.0%$11.00+399.1%-3.0%$207.41M$12.62M0.00220Gap Up Related Companies and Tools Related Companies Entrada Therapeutics Alternatives Sagimet Biosciences Alternatives enGene Alternatives GENFIT Alternatives CARGO Therapeutics Alternatives AC Immune Alternatives Heron Therapeutics Alternatives Organigram Global Alternatives Aardvark Therapeutics Alternatives Innate Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DTIL) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access